Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$106.52 USD

106.52
379,870

-1.99 (-1.83%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $106.51 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Genomic Health Prostate Cancer Business Solid, Cost Woes Stay

by Zacks Equity Research

Within the prostate cancer space, Genomic Health (GHDX) is seeing increasing private coverage for the Oncotype DX GPS test. Costs and operating expenses continue to rise.

    Zacks Equity Research

    Here's Why You Should Invest in athenahealth (ATHN) Now

    by Zacks Equity Research

    Focus on cloud-based services and a lifted guidance for 2018 make athenahealth (ATHN) an attractive pick.

      Zacks Equity Research

      HealthEquity (HQY) Beats Q2 Earnings & Revenue Estimates

      by Zacks Equity Research

      Strong HSA Member growth boosts HealthEquity's (HQY) results in Q2. A strong guidance raises investors??? optimism.

        Zacks Equity Research

        Here's Why You Should Hold On to Baxter (BAX) Stock Now

        by Zacks Equity Research

        Baxter's (BAX) cyclophosphamide performance continues to remain dismal. Nevertheless, the company witnesses positive tidings of other products on the regulatory front.

          Zacks Equity Research

          Why Integer (ITGR) is a Top Pick for Momentum Investors

          by Zacks Equity Research

          Does Integer (ITGR) have what it takes to be a top stock pick for momentum investors? Let's find out.

            Zacks Equity Research

            Amedisys Ties Up With Medalogix to Boost Home Health Unit

            by Zacks Equity Research

            Amedisys (AMED) pursues deals to boost Home Health business.

              Zacks Equity Research

              Cooper Companies (COO) Earnings Miss & Revenues Beat in Q3

              by Zacks Equity Research

              Cooper (COO) gains from solid CSI revenues in Q3; international revenues surge.

                Zacks Equity Research

                Here's Why You Should Invest in Veeva (VEEV) Stock Right Now

                by Zacks Equity Research

                Strong fundamentals and a solid Q2 aid Veeva (VEEV).

                  Zacks Equity Research

                  Glaukos (GKOS) Jumps: Stock Rises 7.2%

                  by Zacks Equity Research

                  Glaukos (GKOS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

                    Zacks Equity Research

                    Illumina MiSeq Dx Okayed in China, NGS Platform Gets a Boost

                    by Zacks Equity Research

                    Illumina's (ILMN) receipt of CNDA approval for MiSeq Dx Sequencing System is expected to expand customer base and boost the top line.

                      Zacks Equity Research

                      Here's Why You Should Invest in Phibro (PAHC) Right Now

                      by Zacks Equity Research

                      Phibro (PAHC) sees improvement across all segments. The Animal Health business has been a key contributor.

                        Zacks Equity Research

                        Patterson Companies (PDCO) Misses Q1 Earnings Estimates

                        by Zacks Equity Research

                        Patterson Companies' (PDCO) adjusted earnings declines considerably on a year-over-year basis in Q1. Lackluster performance by the dental unit is a concern.

                          Zacks Equity Research

                          Here's Why You Should Buy Inogen (INGN) Stock Right Now

                          by Zacks Equity Research

                          Inogen (INGN) gains from strong Q2 results and bright global prospects.

                            Zacks Equity Research

                            Here's Why You Should Invest in Genomic Health (GHDX) Now

                            by Zacks Equity Research

                            Genomic Health (GHDX) gains ground on growing adoption of prostate cancer test and solid international scenario.

                              Zacks Equity Research

                              Ecolab's Nalco Pairs With XOS to Boost Global Energy Unit

                              by Zacks Equity Research

                              Ecolab's (ECL) Nalco Champion's 3D CRUDEFLEX will integrate XOS' Clora Online; market prospects bright.

                                Zacks Equity Research

                                Here's Why You Should Hold On to Stryker (SYK) Stock Now

                                by Zacks Equity Research

                                Challenging global economic conditions and supply-side issues are major deterrents to Stryker's (SYK) top line in the near term. The company's significant exposure to robotics is a positive.

                                  Zacks Equity Research

                                  New Buyouts Aid Boston Scientific Amid Dull Pacemaker Sales

                                  by Zacks Equity Research

                                  Boston Scientific (BSX) continues to adopt organic as well as inorganic routes for success. However, sluggish global pacemaker sales continue to disappoint.

                                    Zacks Equity Research

                                    Phibro Animal (PAHC) Q4 Earnings Beat, Sales Improve Y/Y

                                    by Zacks Equity Research

                                    Phibro (PAHC) witnesses year-over-year improvement across all segments in Q4.

                                      Zacks Equity Research

                                      Wright Medical Buys Cartiva to Boost Lower Extremities Unit

                                      by Zacks Equity Research

                                      Wright Medical's (WMGI) addition of Synthetic Cartilage Implant is likely to drive revenues in 2019; raised guidance for 2018 encourages.

                                        Zacks Equity Research

                                        Here's Why You Should Hold On to DexCom (DXCM) Stock Now

                                        by Zacks Equity Research

                                        DexCom (DXCM) is expected to benefit from lucrative prospects in the diabetes market. However, the company's margins were under pressure in the last reported quarter.

                                          Zacks Equity Research

                                          STERIS (STE) Strategic Growth Strong, Competition a Woe

                                          by Zacks Equity Research

                                          STERIS' (STE) beneficial underlying market trends along with new product and service offerings are impressive. Meanwhile, the company worries over facing a severe competition.

                                            Zacks Equity Research

                                            Bruker to Expand Molecular Diagnostics Arm With Hain Buyout

                                            by Zacks Equity Research

                                            Hain's molecular diagnostics solutions of bacterial and viral infections are expected to compliment Bruker's (BRKR) MALDI Biotyper and IR Biotyper microbiology platforms.

                                              Zacks Equity Research

                                              Omnicell Patient Engagement Unit to Aid Medication Adherence

                                              by Zacks Equity Research

                                              Omnicell's (OMCL) revamped Patient Engagement platform likely to aid core Medication Adherence Unit; market looks promising.

                                                Zacks Equity Research

                                                Here's Why You Should Invest in Integer (ITGR) Stock Now

                                                by Zacks Equity Research

                                                Integer Holdings (ITGR) gains on strong quarterly performance. The company is likely to gain from the Cardio & Vascular, Neuromodulation and Non-Medical Electrochem markets.

                                                  Zacks Equity Research

                                                  Cerner, Duke Clinical Research Launch Risk Calculator App

                                                  by Zacks Equity Research

                                                  Cerner (CERN) launches new Risk Calculator app that will check cardiac risk. The company's relentless efforts to digitize its EHR systems is commendable.